ClinicalTrials.gg
RecruitingNCT07015190Updated May 6, 2026

Neoadjuvant Darovasertib in Primary Uveal Melanoma

A Phase 3 interventional study of Darovasertib and Primary Local Therapy in Uveal Melanoma, sponsored by IDEAYA Biosciences. Recruiting at 94 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by IDEAYA Biosciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 190 studies in Uveal Melanoma with a site in United States — 25 open to participants now, 50 under way, 7 of them phase 3. Uveal Melanoma · United States.

Planned enrollment
2nd of 162
520 · median 36
Started
2026
with 5 others
Phase 3
10 of 190
3 open now
Primary completion
2030-10
later than 41 of 49 live
Registered
183rd of 190
by date
Lead sponsor
5 of 190
IDEAYA Biosciences

Among the 190 studies in Uveal Melanoma with a site in United States, this one is the 2nd largest by planned enrollment of the 162 interventional ones that give a count, is one of 6 that started in 2026, is one of 10 in phase 3, reaches primary completion later than 41 of the 49 other live ones, and was the 183rd registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

25 of the 190 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

Read the detailed description

The study is divided into 2 cohorts of patients with primary uveal melanoma requiring either plaque brachytherapy or enucleation.

In cohort 1, patients in the treatment arm will receive neoadjuvant darovasertib followed by plaque brachytherapy compared to immediate plaque brachytherapy (control arm).

In cohort 2, the treatment arm will receive neoadjuvant darovasertib followed by definitive primary local therapy (i.e., plaque brachytherapy, proton beam radiation, or enucleation). Subjects in the control arm will go onto immediate enucleation.

Subjects will then receive primary local therapy following neoadjuvant darovasertib.

All patients will be followed for up to 3 years to assess longer term outcomes such as vision and tumor recurrence.

03

Conditions studied

  • Uveal Melanoma

Keywords

  • Uveal Melanoma
  • Plaque Brachytherapy
  • Enucleation
  • Neoadjuvant
  • Darovasertib
  • IDE 196
  • Ocular Melanoma
  • Choroidal Melanoma
  • Ophthalmology
  • Ocular Oncology
  • Melanoma
  • Protein Kinase C
  • GNAQ
  • GNA11
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary non- uveal melanoma
  • Able and willing to provide written, before initiation of any study-related procedures, and in the opinion of the Investigator, to comply with all study requirements
  • 0 or 1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Previous treatment for UM
  • Evidence of UM
  • Attributes that necessitate enucleation regardless of response to therapy
  • Evidence of progressive secondary underlying ocular disease that would confound longitudinal VA assessments
  • Presence of a malignant disease other than the one being treated in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Darovasetib followed by definitive primary local therapy (i.e., PB, proton beam radiation, or enucleation)

    Drug: Darovasertib

  • Active comparator
    Control Arm

    Immediate Primary Local therapy

    Procedure: Primary Local Therapy

Interventions

  • Dosed orally, twice daily (28-day/ cycle

    Also known as: IDE 196

  • ProcedurePrimary Local Therapy

    Plaque Brachytherapy or Enucleation

06

What researchers measure

Primary outcomes

  1. Cohort 1: To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control Arm

    Loss of Best Corrected Visual Acuity (BCVA) of ≥ 15 letters using Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA

    Time frame: Approximately 3 years

  2. Cohort 2: To demonstrate the ability to salvage the eye and prevent enucleation in the Treatment Arm

    Eye preservation rate

    Time frame: Approximately 2 years

07

Study locations

25 of 94 sites recruiting
  • Mayo Clinic Scottsdale - PPDS
    Scottsdale, Arizona 85259, United States
    Recruiting
    • Odette Houghton, MD Principal Investigator · Contact
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
    Not yet recruiting
    • Gregory Daniels, MD Principal Investigator · Contact
  • Jules Stein Eye Institute
    Los Angeles, California 90024, United States
    Not yet recruiting
    • Tara McCannel, MD Principal Investigator · Contact
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Not yet recruiting
    • Gino In, MD, Principal Investigator · Contact
  • University of California Irvine Medical Center
    Orange, California 92868, United States
    Not yet recruiting
    • Poorva Vaidya, MD Principal Investigator · Contact
  • Stanford Comprehensive Cancer Center
    Palo Alto, California 94304, United States
    Recruiting
    • Pauline Funchain, MD Principal Investigator · Contact
  • Kaiser Permanente-Riverside Medical Center
    Riverside, California 92505-3043, United States
    Recruiting
    • Helen Moon, MD Principal Investigator · Contact
  • UCSF Wayne and Gladys Valley Center for Vision
    San Francisco, California 94143, United States
    Not yet recruiting
    • Armin Afshar, MD, Principal Investigator · Contact
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
    Recruiting
    • Sapna Patel, MD Principal Investigator · Contact
  • The Melanoma and Skin Cancer Institute
    Englewood, Colorado 80113-2791, United States
    Not yet recruiting
    • Ryan Weight, MD Principal Investigator · Contact
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
    Recruiting
    • Bently Doonan, MD Principal Investigator · Contact
  • USF Health Eye Institute
    Tampa, Florida 33612-6601, United States
    Not yet recruiting
    • Jorge Agi, MD Principal Investigator · Contact
  • Moffit Cancer Center
    Tampa, Florida 33612, United States
    Not yet recruiting
    • Nikhil Khushalani, MD, Principal Investigator · Contact
  • Wilmer Eye Institute
    Baltimore, Maryland 21287-0005, United States
    Recruiting
    • James Handa, MD Principal Investigator · Contact
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Not yet recruiting
    • Kamaneh Montazeri, MD Principal Investigator · Contact
  • W Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
    Not yet recruiting
    • Hakan Demirci, MD Principal Investigator · Contact
  • The Cancer and Hematology Centers of West Michigan (CHCWM)
    Grand Rapids, Michigan 49503, United States
    Recruiting
    • Sreenivasa Chandana, MD Principal Investigator · Contact
  • Mayo Clinic - PPDS
    Rochester, Minnesota 55905, United States
    Recruiting
    • Lauren Dalvin, MD Principal Investigator · Contact
  • TIERING Percentiles
    Omaha, Nebraska 68105, United States
    Not yet recruiting
    • Pukhraj Rishi, MD Principal Investigator · Contact
  • Herbert Irving Comprehensive Cancer Center
    New York, New York 10032, United States
    Recruiting
    • Benjamin Izar, MD Principal Investigator · Contact
  • Memorial Sloan Kettering Cancer Center - 1275 York Ave
    New York, New York 10065-6635, United States
    Not yet recruiting
    • Jasmine Francis, MD Principal Investigator · Contact
  • Northwell Health Cancer Institute
    New York, New York 11042, United States
    Not yet recruiting
    • Shaheer Khan, MD Principal Investigator · Contact
  • Cole Eye Institute-9500 Euclid Ave
    Cleveland, Ohio 44195, United States
    Not yet recruiting
    • Lucy Kennedy, MD Principal Investigator · Contact
  • Ohio State Eye and Ear Institute
    Columbus, Ohio 43212, United States
    Not yet recruiting
    • Colleen Cebulla, MD Principal Investigator · Contact
  • Retina Consultants of Oklahoma
    Oklahoma City, Oklahoma 73112, United States
    Not yet recruiting
    • Brian Firestone, MD, Principal Investigator · Contact
  • Jefferson Health Honickman Center
    Philadelphia, Pennsylvania 19107, United States
    Not yet recruiting
    • Marlana Orloff, MD Principal Investigator · Contact
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Not yet recruiting
    • Yana Najjar, MD Principal Investigator · Contact
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Meredith McKean, MD Principal Investigator · Contact
  • Vanderbilt Eye Institute
    Nashville, Tennessee 37232, United States
    Not yet recruiting
    • Paul Sternberg, MD, Principal Investigator · Contact
  • Austin Retina Associates - Central
    Austin, Texas 78705, United States
    Recruiting
    • Shelley Ghafoori, MD Principal Investigator · Contact
  • Texas Retina Associates - Dallas
    Dallas, Texas 75231, United States
    Recruiting
    • Timothy Fuller, MD Principal Investigator · Contact
  • University of Texas Southwestern Medical Center-5323 Harry Hines Blvd
    Dallas, Texas 75390-9057, United States
    Recruiting
    • Sanjay Chandrasekaran, MD Principal Investigator · Contact
  • Retina Consultants of Texas - (Houston)
    Houston, Texas 77030-2727, United States
    Not yet recruiting
    • Amy Schefler, MD Principal Investigator · Contact
  • Augusta Health, Center for Cancer and Blood Disorders
    Fishersville, Virginia 22939, United States
    Not yet recruiting
    • Kelvin Rayborn, MD Principal Investigator · Contact
  • University of Wisconsin Health
    Madison, Wisconsin 53705-3644, United States
    Not yet recruiting
    • Michael Altaweel, MD Principal Investigator · Contact
  • Gallipoli Medical Research Foundation
    Greenslopes, Queensland QLD 4120, Australia
    Not yet recruiting
    • Victoria Atkinson, MD, Principal Investigator · Contact
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
    Not yet recruiting
    • Rachel Roberts-Thomson, MD Principal Investigator · Contact
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Not yet recruiting
    • Mark Shackleton, MD Principal Investigator · Contact
  • The Crown Princess Mary Cancer Centre (Westmead Hospital), NSW 214
    Westmead, NSW 2145, Australia
    Not yet recruiting
    • Matteo Carlino, MD, Principal Investigator · Contact
  • LKH-Universitätsklinikum Graz
    Graz, 8036, Austria
    Not yet recruiting
    • Thomas Georgi, MD Principal Investigator · Contact
  • Universitätsklinikum Innsbruck
    Innsbruck, 6020, Austria
    Not yet recruiting
    • Matus Rehak, MD Principal Investigator · Contact
  • Universitätsklinikum AKH Wien
    Vienna, 1090, Austria
    Not yet recruiting
    • Roman Dunavölgyi, MD Principal Investigator · Contact
  • Cliniques Universitaires Saint-Luc - PPDS
    Brussels, 1200, Belgium
    Recruiting
    • Jean-Francois Baurain, MD Principal Investigator · Contact
  • UZ Leuven - PPDS
    Leuven, 3000, Belgium
    Not yet recruiting
    • Joachim Van Calster, MD Principal Investigator · Contact
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
    Not yet recruiting
    • John Walker, MD, Principal Investigator · Contact
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Marcus Butler, MD Principal Investigator · Contact
  • Ustredni vojenska nemocnice - Vojenska fakultni nemocnice Praha
    Prague, Prague 169 02, Czechia
    Recruiting
    • Zuzana Hradcova, MD Principal Investigator · Contact
  • Rigshospitalet
    Copenhagen O, Capital 2100, Denmark
    Not yet recruiting
    • Jens Kiilgaard, MD Principal Investigator · Contact
  • Aarhus Universitetshospital
    Aarhus, Central Jutland 8200, Denmark
    Not yet recruiting
    • Peter Skov Jensen, MD Principal Investigator · Contact
  • East Tallinn Central Hospital-Pärnu road 104
    Tallinn, Harju 11312, Estonia
    Not yet recruiting
    • Elen Vettus, MD Principal Investigator · Contact
  • CHU de Nice-Hôpital Pasteur
    Nice, Alpes-Maritimes 6000, France
    Not yet recruiting
    • Sacha Nahon-Estève, MD Principal Investigator · Contact
  • Centre Retine Gallien - Bordeaux
    Bordeaux, Gironde 33000, France
    Not yet recruiting
    • Laurence Rosier, MD Principal Investigator · Contact
  • CHU de Rennes - Hôpital Pontchaillou
    Rennes, Ille-et-Vilaine 35000, France
    Not yet recruiting
    • Frederic Mouriaux, MD Principal Investigator · Contact
  • Institut Curie - Hôpital de Paris
    Paris, Paris 75248, France
    Not yet recruiting
    • Alexandre Matet, MD Principal Investigator · Contact
  • Centre Hospitalier National D'ophtalmologie Des Quinze Vingts
    Paris, 75571, France
    Not yet recruiting
    • Sarah Tick, MD Principal Investigator · Contact
  • Universitätsklinikum Tübingen
    Tübingen, Baden-Wurttemberg 72076, Germany
    Not yet recruiting
    • Daniela Süsskind, MD Principal Investigator · Contact
  • Universitätsklinikum Ulm
    Ulm, Baden-Wurttemberg 89075, Germany
    Not yet recruiting
    • Armin Wolf, MD Principal Investigator · Contact
  • Hautklinik Erlangen
    Erlangen, Bavaria 91054, Germany
    Not yet recruiting
    • Carola Berking, MD Principal Investigator · Contact
  • Universitätsklinikum Essen
    Essen, North Rhine-Westphalia 45147, Germany
    Not yet recruiting
    • Halime Kalkavan, MD Principal Investigator · Contact
  • Städtisches Klinikum Dessau
    Dessau, Saxony-Anhalt 6847, Germany
    Not yet recruiting
    • Lothar Krause, MD Principal Investigator · Contact
  • Charité - Universitätsmedizin Berlin
    Berlin, 12203, Germany
    Not yet recruiting
    • Antonia Joussen, MD Principal Investigator · Contact
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
    Not yet recruiting
    • Thomas Ach, MD Principal Investigator · Contact
  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck
    Lübeck, 23562, Germany
    Not yet recruiting
    • Svenja Sonntag, Principal Investigator, MD · Contact
  • Universitätsklinikum Giessen und Marburg - Marburg (UKGM)
    Marburg, 35043, Germany
    Not yet recruiting
    • Walter Sekundo, MD Principal Investigator · Contact
  • Universitätsklinikum Würzburg
    Würzburg, 97080, Germany
    Not yet recruiting
    • Andreas Berlin, MD Principal Investigator · Contact
  • PAGNI-University General Hospital of Heraklion
    Heraklion, Irakleio 715 00, Greece
    Not yet recruiting
    • Efstathios Detorakis, MD Principal Investigator · Contact
  • University General Hospital of Larissa
    Larissa, Larissa 41 110, Greece
    Not yet recruiting
    • Sofia Androudi, MD Principal Investigator · Contact
  • AHEPA University General Hospital of Thessaloniki
    Thessaloniki, Thessaloníki 546 36, Greece
    Not yet recruiting
    • Konstantinos Boboridis, MD Principal Investigator · Contact
  • The Chaim Sheba Medical Center - PPDS
    Ramat Gan, Central District 5262100, Israel
    Recruiting
    • Vicktoria Vishnevskia-Dai, MD Principal Investigator · Contact
  • Hadassah Medical Center - PPDS
    Jerusalem, Jerusalem 91120, Israel
    Recruiting
    • Shahar Frenkel, MD Principal Investigator · Contact
  • Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale
    Naples, Campania 80131, Italy
    Not yet recruiting
    • Paolo Ascierto, MD Principal Investigator · Contact
  • ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco
    Milan, Milan 20157, Italy
    Not yet recruiting
    • Marco Pellegrini, MD Principal Investigator · Contact
  • Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia
    Perugia, Perugia, Italy
    Not yet recruiting
    • Mario Mandalà, MD Principal Investigator · Contact
  • Azienda Ospedaliera Universitaria Careggi
    Florence, Tuscany 50134, Italy
    Recruiting
    • Cinzia Mazzini, MD Principal Investigator · Contact
  • Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia
    Pisa, 56124, Italy
    Not yet recruiting
    • Federica Genovesi Ebert, MD Principal Investigator · Contact
  • Fondazione Policlinico Universitario A Gemelli - Rome - PPDS
    Rome, 168, Italy
    Not yet recruiting
    • Ernesto Rossi, MD Principal Investigator · Contact
  • Erasmus MC
    Rotterdam, South Holland 3015 GD, Netherlands
    Not yet recruiting
    • Emine Kiliç-Ciğirci, MD Principal Investigator · Contact
  • Auckland Eye
    Auckland, Auckland 1050, New Zealand
    Not yet recruiting
    • Riyaz Bhikoo, MD Principal Investigator · Contact
  • Uniwersytecki Szpital Kliniczny w Poznaniu- Dluga 1/2
    Poznan, Greater Poland Voivodeship 61-848, Poland
    Not yet recruiting
    • Iwona Rospond-Kubiak, MD Principal Investigator · Contact
  • WIM-PIB, Centralny Szpital Kliniczny MON
    Warsaw, Masovian Voivodeship 04-141, Poland
    Not yet recruiting
    • Izabela Nowak-Gospodarowicz, MD Principal Investigator · Contact
  • Uniwersyteckie Centrum Kliniczne w Gdansku - Debinki 7
    Gdansk, Pomeranian Voivodeship 80-214, Poland
    Not yet recruiting
    • Kamil Drucis, MD Principal Investigator · Contact
  • Fakultna nemocnica s poliklinikou F. D. Roosevelta
    Banská Bystrica, 975 17, Slovakia
    Not yet recruiting
    • Ladislav Janco, MD Principal Investigator · Contact
  • Institute of Oncology Ljubljana
    Ljubljana, Ljubljana 1000, Slovenia
    Not yet recruiting
    • Janja Ocvirk, MD Principal Investiagtor · Contact
  • Hospital Clinico Universitario de Santiago
    Santiago de Compostela, A Coruña 15706, Spain
    Recruiting
    • Maria José Blanco Teijeiro, MD Principal Investigator · Contact
  • Hospital Universitario de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 8907, Spain
    Not yet recruiting
    • Jose Maria Caminal Mitjana, MD Principal Investigator · Contact
  • Clinica Universidad Navarra
    Pamplona, Navarre 31008, Spain
    Recruiting
    • Alfredo Garcia Layana, MD Principal Investigator · Contact
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, Valencia 46026, Spain
    Not yet recruiting
    • Rafael Martínez-Costa Pérez, MD Principal Investigator · Contact
  • Hospital Clinico Universitario de Valladolid
    Valladolid, Valladolid 47003, Spain
    Recruiting
    • Ciro Garcia-Alvarez, MD Principal Investigator · Contact
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
    Recruiting
    • Francisco Espejo-Arjona, MD Principal Investigator · Contact
  • Universitätsspital Basel
    Basel, 4031, Switzerland
    Recruiting
    • Andreas Schmitt, MD Principal Investigator · Contact
  • Universitätsspital Zürich
    Zurich, 8091, Switzerland
    Recruiting
    • Egle Ramelyte, MD Principal Investigator · Contact
  • Clatterbridge Cancer Centre - Liverpool - NWCRN - PPDS
    Metropolitan Borough of Wirral, Merseyside CH63 4JY, United Kingdom
    Not yet recruiting
    • Joseph Sacco, MD Principal Investigator · Contact
  • University College Hospital
    London, NW1 2BU, United Kingdom
    Not yet recruiting
    • Heather Shaw, MD Principal Investigator · Contact
  • Weston Park Cancer Centre - PPDS
    Sheffield, S10 2TF, United Kingdom
    Not yet recruiting
    • Krishnakumar Garadi, MD Principal Investigator · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Oct 2030, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 11, 2025
StartActual
Jan 25, 2026
Primary completionEst.
Oct 2030
CompletionEst.
Mar 2031
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07015190
Lead sponsor
IDEAYA Biosciences
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jan 25, 2026
Primary completion
Oct 2030 (estimated)
Completion
Mar 2031 (estimated)
Last update
May 6, 2026

Study contacts

IDEAYA Clinical Trials
Contact
IDEAYAClinicalTrials@ideayabio.com
+1-855-433-2246
Mwe Mwe Chao, MD
Contact
mchao@ideayabio.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darovasertib

Start the discussion